From fetal life through childhood, the gland trains immune cells called T cells to distinguish self from non-self. Although MG and other autoimmune diseases are not hereditary, genetic susceptibility does appear to play a role. It seems likely that genetic factors also contribute to the pathogenesis of MG.
Most studies suggest that if people have a relative with an autoimmune disease, their risk of getting an autoimmune disease is increased — the closer the relative, the higher the risk.
Even for identical twins, however, that risk is relatively small. Also, people who already have one autoimmune disease have a greater risk of developing another one. The most common of these are autoimmune thyroid disease, rheumatoid arthritis, and systemic lupus erythematosus a disease that affects multiple organs.
Skip to main content. Search MDA. Search Donate. Myasthenia Gravis MG. It grows gradually until puberty, and then gets smaller and is replaced by fat. Throughout childhood, the thymus plays an important role in the development of the immune system because it is responsible for producing T-lymphocytes or T cells, a specific type of white blood cell that protects the body from viruses and infections. In many adults with myasthenia gravis, the thymus gland remains large.
People with the disease typically have clusters of immune cells in their thymus gland and may develop thymomas tumors of the thymus gland. Thymomas are most often harmless, but they can become cancerous. Scientists believe the thymus gland may give incorrect instructions to developing immune cells, ultimately causing the immune system to attack its own cells and tissues and produce acetylcholine receptor antibodies—setting the stage for the attack on neuromuscular transmission.
Myasthenia gravis affects both men and women and occurs across all racial and ethnic groups. It most commonly impacts young adult women under 40 and older men over 60 , but it can occur at any age, including childhood. Myasthenia gravis is not inherited nor is it contagious.
Occasionally, the disease may occur in more than one member of the same family.. Although myasthenia gravis is rarely seen in infants, the fetus may acquire antibodies from a mother affected with myasthenia gravis—a condition called neonatal myasthenia. Rarely, children of a healthy mother may develop congenital myasthenia. This is not an autoimmune disorder but is caused by defective genes that produce abnormal proteins in the neuromuscular junction and can cause similar symptoms to myasthenia gravis.
Because weakness is a common symptom of many other disorders, the diagnosis of myasthenia gravis is often missed or delayed sometimes up to two years in people who experience mild weakness or in those individuals whose weakness is restricted to only a few muscles.
Today, myasthenia gravis can generally be controlled. There are several therapies available to help reduce and improve muscle weakness. With treatment, most individuals with myasthenia can significantly improve their muscle weakness and lead normal or nearly normal lives. Some cases of myasthenia gravis may go into remission—either temporarily or permanently— and muscle weakness may disappear completely so that medications can be discontinued.
Stable, long-lasting complete remissions are the goal of thymectomy and may occur in about 50 percent of individuals who undergo this procedure. The mission of the National Institute of Neurological Disorders and Stroke NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
Although there is no cure for myasthenia gravis, management of the disorder has improved over the past 30 years. There is a greater understanding about the causes, structure and function of the neuromuscular junction, the fundamental aspects of the thymus gland and of autoimmunity.
Technological advances have led to more timely and accurate diagnosis of myasthenia gravis and new and enhanced therapies have improved treatment options. Researchers are working to develop better medications, identify new ways to diagnose and treat individuals, and improve treatment options. After an injury, a process of muscle degeneration occurs, followed by the activation of the SCs that proliferate, become so-called myoblasts, differentiate, and fuse to give rise to new fibers Recently, the article by Attia et al.
Besides, SCs isolated from MG muscles proliferate as myoblasts and differentiate more actively than cells from control muscles. In addition, after a muscle injury induced in the EAMG mouse model, several changes were observed: a decrease in fiber size and MyoG mRNA expression and an increase in the number of fibers and embryonic myosin heavy-chain mRNA expression.
These alterations suggest that as a result of the autoimmune attack, there is a delay in maturation of the muscle fibers. More likely, the binding of anti-AChR Ab to their antigens impairs the NMJ see the mechanisms above and alters the production of several paracrine factors, micro-vesicles, or exosomes by the muscle. These factors could then induce paracrine effects on the neighboring SCs associated with subtle modifications of the epigenetic signatures Figure 1B , Number 9.
From a clinical perspective, symptom exacerbation upon sports practice or after a muscle injury could also be due to difficulties for MG patients to regenerate their muscle. In MG disease, the Ab to the different components of the NMJ have pathogenic consequences that are more extended than a focused effect on the target antigens.
In other autoimmune diseases, the attack by the Ab and by the MAC would have induced the death of the target cells. In the case of the muscle, this does not occur, but activation of molecular transcription and signaling pathways, mechanisms of compensation, and biological effects on local cell types such as satellite cells demonstrate that the muscle responds actively.
Thus, the muscle is not a passive target in MG but interacts dynamically with its environment in several ways. However, the number of studies examining theses processes is still quite limited. A better appraisal of these processes would allow identifying new mechanisms and pathways, and new levels for symptomatic medical interventions.
New approaches are rapidly developing to model MG and facilitate such studies. AB conceived and designed the figure. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Nat Med. Development of the neuromuscular junction: genetic analysis in mice. J Physiol Paris. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
Ann Neurol. Diagnostic utility of cortactin antibodies in myasthenia gravis. Ann N Y Acad Sci. Autoantibodies to agrin in myasthenia gravis patients.
Berrih-Aknin S. Myasthenia Gravis: Paradox versus paradigm in autoimmunity. J Autoimmun. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev. Randomized trial of thymectomy in myasthenia gravis. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve. Myasthenia gravis.
Nat Rev Dis Prim. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. Genetic basis of myasthenia gravis - a comprehensive review. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. J Intern Med. Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. Howard JF, Howard Jr. Myasthenia gravis: the role of complement at the neuromuscular junction.
Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase MuSK. J Biol Chem. To build a synapse: signaling pathways in neuromuscular junction assembly.
The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Current concepts in neuromuscular transmission. Br J Anaesth. Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting. Physiol Rev. Slater CR. The structure of human neuromuscular junctions: some unanswered molecular questions. Int J Mol Sci. Nishimune H, Shigemoto K. Practical anatomy of the neuromuscular junction in health and disease.
Neurol Clin. Safety factor at the neuromuscular junction. Prog Neurobiol. Plomp JJ. Trans-synaptic homeostasis at the myasthenic neuromuscular junction. Front Biosci. Engel AG. Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes. J Neurol Neurosurg Psychiatry. Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients.
How myasthenia gravis alters the safety factor for neuromuscular transmission. J Neuroimmunol. Neuromuscular synapse electrophysiology in myasthenia gravis animal models. Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles: safety factor in ocular myasthenia. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?
Pathological mechanisms in experimental autoimmune myasthenia gravis. J Exp Med. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis.
0コメント